1 Result(s)

Article

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

The antitumour action of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is mediated through tumour-selective antivascular effects and cytokine induction. This clinical phase I trial was conducted to examine its ...

M B Jameson, P I Thompson, B C Baguley, B D Evans, V J Harvey… in British Journal of Cancer (2003)